ישראל - עברית - Ministry of Health

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 20 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

ישראל - עברית - Ministry of Health

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 10 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - methylprednisolone acetate - תרחיף להזרקה - methylprednisolone acetate 40 mg/ml - methylprednisolone - methylprednisolone - for the treatment of conditions responsive to steroid injection therapy.

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - ספריי לאף - b/phuket/3073/2013 (b/yamagata lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/darwin/9/2021 (h3n2)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 7 ±0.5 log10 ffu^a / 0.2 ml - influenza, inactivated, split virus or surface antigen - influenza, purified antigen - flumist quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza a subtype viruses ad type b viruses contained in the vaccine. flumist quadrivalent is approved for use in persons 2 through 49 years of age.

ישראל - עברית - Ministry of Health

padagis israel agencies ltd, israel - vinorelbine as tartrate - קפסולות - vinorelbine as tartrate 20 mg - vinorelbine - vinorelbine - for the treatment of non small cell lung cancer. for the treatment of advanced breast cancer.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - interferon alfa 2a 4.5 miu / 0.5 ml - solution for injection - interferon alfa-2a - roferon-a is indicated for the treatment of:- condylomata acuminata - hairy cell leukaemia.- aids patients with progressive, asymptomatic kaposi's sarcoma who have a cd4 count > 250/mm3.- chronic phase philadelphia-chromosome positive chronic myelogenous leukaemia. roferon-a is not an alternative treatment for cml patients who have an hla-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. it is still unknown whether roferon-a can be considered as a treatment with a curative potential in this indication.- adult patients with histologically proven chronic hepatitis b who have markers for viral replication, i.e., those who are positive for hbv dna or hbeag.- adult patients with histologically proven chronic hepatitis c who are positive for hcv antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation.- follicular non-hodgkin’s lymphoma.- advanced renal cell carcinoma.- patients with ajcc stage ii m

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - interferon alfa 2a 6 miu / 0.5 ml - solution for injection - interferon alfa-2a - roferon-a is indicated for the treatment of:- condylomata acuminata - hairy cell leukaemia.- aids patients with progressive, asymptomatic kaposi's sarcoma who have a cd4 count > 250/mm3.- chronic phase philadelphia-chromosome positive chronic myelogenous leukaemia. roferon-a is not an alternative treatment for cml patients who have an hla-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. it is still unknown whether roferon-a can be considered as a treatment with a curative potential in this indication.- adult patients with histologically proven chronic hepatitis b who have markers for viral replication, i.e., those who are positive for hbv dna or hbeag.- adult patients with histologically proven chronic hepatitis c who are positive for hcv antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation.- follicular non-hodgkin’s lymphoma.- advanced renal cell carcinoma.- patients with ajcc stage ii m

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - interferon alfa 2a 9 miu / 0.5 ml - solution for injection - interferon alfa-2a - roferon-a is indicated for the treatment of:- condylomata acuminata - hairy cell leukaemia.- aids patients with progressive, asymptomatic kaposi's sarcoma who have a cd4 count > 250/mm3.- chronic phase philadelphia-chromosome positive chronic myelogenous leukaemia. roferon-a is not an alternative treatment for cml patients who have an hla-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. it is still unknown whether roferon-a can be considered as a treatment with a curative potential in this indication.- adult patients with histologically proven chronic hepatitis b who have markers for viral replication, i.e., those who are positive for hbv dna or hbeag.- adult patients with histologically proven chronic hepatitis c who are positive for hcv antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation.- follicular non-hodgkin’s lymphoma.- advanced renal cell carcinoma.- patients with ajcc stage ii m

ישראל - עברית - Ministry of Health

novartis israel ltd - nepafenac - תרחיף לעין - nepafenac 0.1 % - nepafenac - nepafenac - prevention and treatment of postoperative pain and inflammation associated with cataract surgery and reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.

ישראל - עברית - Ministry of Health

novartis israel ltd - travoprost - תמיסה לעין - travoprost 0.004 %w/v - travoprost - travoprost - for the reduction of elevated intra ocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other iop lowering medications or insufficiently responsive to another iop lowering medication.